# New schizophrenia clinical trials, last 30 days: 25 (2026)

Updated November 19, 2026.

25 new trials for schizophrenia were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New schizophrenia clinical trials, last 30 days: 25 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/new/schizophrenia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 17
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943559 | Mechanisms and Interventions of Treatment-Resistant Schizophrenia Based on Brain Organoids | Shanghai Mental Health Center | Observational | Not yet recruiting | Treatment-resistant Schizophrenia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943559) |
| November 17, 2026 | NCT07942441 | The Effect of Mindfulness-Based Psychoeducation on Psychological Resilience and Insight in Individuals Diagnosed With Schizophrenia | Dicle University | Not applicable | Completed | SCHIZOPHRENIA 1 (Disorder), Mindfulness, Insight, Resilience, Mental Health | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942441) |
| November 17, 2026 | NCT07940712 | Cognitive Augmentation, Remediation, and TDCS for Schizophrenia | Beth Israel Deaconess Medical Center | Not applicable | Not yet recruiting | Schizophrenia / Schizoaffective Disorder | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940712) |
| November 16, 2026 | NCT07939477 | Multitarget HD-tDCS and Spatial Navigation Memory in Schizophrenia | School of Psychology, Northwest Normal University | Not applicable | Completed | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939477) |
| November 16, 2026 | NCT07939347 | AVATAR Therapy for Distressing Voices in India and Ethiopia | King's College London | Not applicable | Not yet recruiting | Psychosis, Hallucinations | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939347) |
| November 16, 2026 | NCT07938047 | The Effect of Social Cognition and Interaction Training on Patients With Schizophrenia | Central South University | Not applicable | Completed | SCHIZOPHRENIA | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938047) |
| November 16, 2026 | NCT07937761 | Effects of Painting-Based Art Interventions in Individuals With Schizophrenia | Selcuk University | Not applicable | Completed | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937761) |
| November 13, 2026 | NCT07936149 | Nurse-Led Simulation-Based Prosocial Skills Training in Individuals With Schizophrenia | Selcuk University | Not applicable | Completed | SCHIZOPHRENIA 1 (Disorder) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936149) |
| November 13, 2026 | NCT07935746 | θTACS for Schizophrenia (SCZ) | Anhui Medical University | Not applicable | Not yet recruiting | Schizophrenia Disorder | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935746) |
| November 12, 2026 | NCT07932236 | Evaluating Enhanced WELLFOCUS Positive Psychotherapy (EWPPT) and Narrative Enhancement and Cognitive Therapy (NECT) for People With... | City University of Hong Kong | Not applicable | Enrolling by invitation | Schizophrenia | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932236) |
| November 12, 2026 | NCT07931456 | Health Assessment in People With Severe Mental Illness | University of the Basque Country (UPV/EHU) | Observational | Recruiting | Severe Mental Illness, Schizophrenia, Bipolar Disorder, Depression / Major Depressive Disorder | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931456) |
| November 10, 2026 | NCT07927946 | Higher-Dose Maintenance With ERZOFRI 351 mg in Adults With Schizophrenia | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927946) |
| November 10, 2026 | NCT07927790 | Temporal Interference Stimulation Targeting Thalamus for Schizophrenia-Related Cognitive Dysfunction | Central South University | Not applicable | Not yet recruiting | Schizophrenia Disorder, Cognitive Impairments | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927790) |
| November 6, 2026 | NCT07921966 | Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants | Neurelis, Inc. | Phase 1 | Not yet recruiting | Healthy Adult Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921966) |
| November 6, 2026 | NCT07921667 | Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment | International University of La Rioja | Observational | Not yet recruiting | Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921667) |
| November 5, 2026 | NCT07918222 | Sequential Treatment Approaches for Treatment-Resistant Schizophrenia | Shanghai Mental Health Center | Phase 3 | Recruiting | Treatment-resistant Schizophrenia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918222) |
| November 4, 2026 | NCT07917637 | Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia | Sponsor not shown (see the record) | Not applicable | Completed | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917637) |
| November 3, 2026 | NCT07913529 | Time Course of Clozapine-associated Agranulocytosis Over 19 Years | Sheba Medical Center | Observational | Completed | Agranulocytosis, Neutropenia, SCHIZOPHRENIA 1 (Disorder), Treatment-resistant Schizophrenia | 2,020 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913529) |
| November 3, 2026 | NCT07913100 | Real-World Impact of TV-44749 in Adults With Schizophrenia | Teva Branded Pharmaceutical Products R&D LLC | Observational | Not yet recruiting | Schizophrenia | 1,085 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913100) |
| November 3, 2026 | NCT07911787 | Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 476 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911787) |
| November 2, 2026 | NCT07908680 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia | Novartis Pharmaceuticals | Phase 1 | Recruiting | Schizophrenia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908680) |
| October 29, 2026 | NCT07902518 | Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations | Ciusss de L'Est de l'Île de Montréal | Not applicable | Recruiting | Auditory Verbal Hallucinations, Schizophrenia, Schizoaffective Disorder, Psychotic Disorders | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902518) |
| October 28, 2026 | NCT07900893 | Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3 | Washington University School of Medicine | Not applicable | Recruiting | Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900893) |
| October 27, 2026 | NCT07898852 | Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia | Dokuz Eylul University | Not applicable | Not yet recruiting | Schizophrenia, Schizoaffective Disorder, Internalized Stigma, Social Stigma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898852) |
| October 22, 2026 | NCT07887997 | Temporal Interference Stimulation (TI) for Schizophrenia (SCZ) | Anhui Medical University | Not applicable | Not yet recruiting | Schizophrenia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887997) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 15 |
| Observational | 5 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Shanghai Mental Health Center | 2 |
| Central South University | 2 |
| Selcuk University | 2 |
| Anhui Medical University | 2 |
| Dicle University | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| School of Psychology, Northwest Normal University | 1 |
| King's College London | 1 |
| City University of Hong Kong | 1 |
| University of the Basque Country (UPV/EHU) | 1 |
| Neurelis, Inc. | 1 |
| International University of La Rioja | 1 |
| Sheba Medical Center | 1 |
| [Teva Branded Pharmaceutical Products R&D LLC](https://specstream.ai/data/clinical-trials/company/teva-branded-pharmaceutical-products-r-and-d-llc) | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
| Washington University School of Medicine | 1 |
| Dokuz Eylul University | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lebanese restaurants in the United States](https://specstream.ai/data/businesses/lebanese-restaurants/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
- [Smoothie and juice bars in the United States](https://specstream.ai/data/businesses/smoothie-and-juice-bars/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
